Carrying amount of liabilities related to the sale of future royalties.

No definition available.

Name:	depo_LiabilityRelatedToSaleOfFutureRoyalties
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying amount as of the balance sheet date of noncurrent liabilities related to the sale of future royalties and milestones. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).

+ References

No definition available.

+ Details

Name:	depo_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of non-cash interest expense on liability related to sale of future royalties and milestones.

+ References

No definition available.

+ Details

Name:	depo_NonCashInterestExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of non-cash royalty revenue related to sale of future royalties.

+ References

No definition available.

+ Details

Name:	depo_NonCashRoyaltyRevenueFromSaleOfFutureRoyalties
Namespace Prefix:	depo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name:	us-gaap_DebtInstrumentInterestRateEffectivePercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name:	us-gaap_DeferredRevenueRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_MovementInDeferredRevenueRollForward
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=depo_FutureRoyaltyLiabilityArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LIABILITY RELATED TO SALE OF FUTURE ROYALTIES (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended		3 Months Ended	9 Months Ended	0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Sep. 30, 2014	Oct. 18, 2013
Future royalties liability
Royalty and milestone payments received		$ 240,500
Effective interest rate (as a percent)				10.00%
Non-cash PDL royalty revenue	242,808	18,104
Non-cash interest expense on PDL liability	14,646	4,488
Activity within the liability account
Proceeds from sale of future royalties		240,500
Non-cash interest expense recognized	14,646	4,488
Non-cash PDL royalty revenue	(242,808)	(18,104)
Liability related to sale of future royalties, less current portion		177,624
Liability related to sale of future royalties
Future royalties liability
Non-cash PDL royalty revenue			146,956
Non-cash interest expense on PDL liability				14,646
Activity within the liability account
Liability related to sale of future royalties-beginning balance	227,079		166,411	227,079
Non-cash interest expense recognized				14,646
Payments from Depomed to PDL			(19,455)	75,314
Non-cash PDL royalty revenue			(146,956)
Total liability related to sale of future royalties at the end of the period				166,411
Liability related to sale of future royalties \| PDL BioPharma
Future royalties liability
Royalty and milestone payments received					240,500
Activity within the liability account
Proceeds from sale of future royalties					$ 240,500